Key facts

Invented name
Ajovy
Active Substance
fremanezumab
Therapeutic area
Neurology
Decision number
P/0411/2019
PIP number
EMEA-001877-PIP01-15-M02
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of migraine headaches
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Teva GmbH

Tel. +41 552201546
E-mail: info-era-clinical@teva.de

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0411/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab (AJOVY), (EMEA-001877-PIP01-15-M02)

How useful do you find this page?